Filing Flows › Comparisons › PRLD vs CELU
Prelude Therapeutics vs Celularity: PRLD and CELU compared
Prelude Therapeutics is the larger company: $5.7M of revenue in its latest quarter (Q2 2026) against $5.4M for Celularity (Q2 2026). Celularity is more profitable, with an operating margin of -78.0% against -270.9%.
Where the money goes: PRLD and CELU
Prelude Therapeutics (PRLD) · Q2 2026
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Celularity (CELU) · Q2 2026
Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%, net earnings $706K, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Prelude Therapeutics (PRLD) | Celularity (CELU) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5.7M | $5.4M |
| Revenue growth, Y/Y | — | -5% |
| Operating margin | -270.9% | -78.0% |
| Net earnings | −$13.9M | $706K |
| Net margin | -244.1% | 13.0% |
| Operating cash flow | −$15.6M | −$1.1M |
Where the revenue comes from
Celularity
- Product: $4.1M (75%)
- License Royalty and Other: $719K (13%)
- Service: $652K (12%)
Questions
Which is bigger, Prelude Therapeutics or Celularity?
Prelude Therapeutics is the larger company: $5.7M of revenue in its latest quarter (Q2 2026) against $5.4M for Celularity (Q2 2026).
Is Prelude Therapeutics or Celularity growing faster?
Celularity is more profitable, with an operating margin of -78.0% against -270.9%.
More: Prelude Therapeutics earnings · how Prelude Therapeutics makes money · Celularity earnings · how Celularity makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Oct 20, 2026). Fiscal quarters can end on different dates. Not investment advice.